NLS Pharmaceutics (NLSP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NLS Pharmaceutics has announced a merger with Israeli-based Kadimastem Ltd., aiming to strengthen its position in the pharmaceutical market. This strategic move will result in Kadimastem becoming a wholly owned subsidiary of NLS Pharmaceutics, potentially offering new opportunities for investors. The merger also involves the distribution of contingent value rights to NLS shareholders, tied to the future sale of legacy assets.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.